<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">OMEPRAZOLE <img border="0" src="../images/pr.gif"/></span><br/>(o-me'pra-zole)<br/><span class="topboxtradename">Losec <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Prilosec, </span><span class="topboxtradename">Prilosec OTC, </span><span class="topboxtradename">Zegerid<br/></span><b>Classifications:</b> <span class="classification">gastrointestinal agent</span>; <span class="classification">proton pump inhibitor</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg, 20 mg, 40 mg capsules; 20 mg powder for oral suspension</p>
<h1><a name="action">Actions</a></h1>
<p>An antisecretory compound that is a gastric acid pump inhibitor. Suppresses gastric acid secretion by inhibiting the H<sup>+</sup>, K<sup>+</sup>-ATPase enzyme system [the acid (proton H<sup>+</sup>) pump] in the parietal cells.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Suppresses gastric acid secretion relieving gastrointestinal distress and promoting ulcer healing.</p>
<h1><a name="uses">Uses</a></h1>
<p>Duodenal and gastric ulcer. Gastroesophageal reflux disease including severe erosive esophagitis (4 to 8 wk treatment). Long-term
         treatment of pathologic hypersecretory conditions such as Zollinger-Ellison syndrome, multiple endocrine adenomas, and systemic
         mastocytosis. In combination with clarithromycin to treat duodenal ulcers associated with <i>Helicobacter pylori</i>.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Healing or prevention of NSAID-related ulcers.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Long-term use for gastroesophageal reflux disease (GERD), duodenal ulcers; proton pump inhibitors (PPIs), hypersensitivity;
         children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Dysphagia; metabolic or respiratory alkalosis; lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Gastroesophageal Reflux, Erosive Esophagitis, Duodenal Ulcer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 20 mg once/d for 48 wk<br/><br/><span class="indicationtitle">Gastric Ulcer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 20 mg b.i.d. for 48 wk<br/><br/><span class="indicationtitle">Hypersecretory Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 60 mg once/d up to 120 mg t.i.d.<br/><br/><span class="indicationtitle">Duodenal Ulcer Associated with <i>H. pylori</i> </span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 40 mg once/d for 14 d, then 20 mg/d for 14 d, in combination with clarithromycin 500 mg t.i.d. for 14 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give before food, preferably breakfast; capsules must be swallowed whole (do not open, chew, or crush).</li>
<li> 				Note: Antacids may be administered with omeprazole. 			</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, dizziness, fatigue. <span class="typehead">GI:</span> Diarrhea, abdominal pain, nausea, mild transient increases in liver function tests. <span class="typehead">Urogenital:</span> Hematuria, proteinuria. <span class="typehead">Skin:</span> Rash. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Omeprazole has been reported to significantly impair peak <b>cortisol</b> response to exogenous ACTH. This finding is undergoing further investigation.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Concomitant administration of <b>diazepam</b> and omeprazole may increase diazepam concentrations. Concomitant administration of <b>phenytoin</b> and omeprazole may increase <b>phenytoin</b> levels. Concomitant administration of <b>warfarin</b> and omeprazole may increase <b>warfarin</b> levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Poorly absorbed from GI tract; 3040% reaches systemic circulation. <span class="typehead">Onset:</span> 0.53.5 h. <span class="typehead">Peak:</span> Peak inhibition of gastric acid secretion: 5 d. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 80% excreted in urine, 20% in feces. <span class="typehead">Half-Life:</span> 0.51.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor urinalysis for hematuria and proteinuria. Periodic liver function tests with prolonged use.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any changes in urinary elimination such as pain or discomfort associated with urination, or blood in urine.</li>
<li>Report severe diarrhea; drug may need to be discontinued.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>